Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 18 of 18 for “"Vismodegib"”.
-
Vismodegib polymeric nanoparticles for targeting the pancreatic tumour microenvironment
… outcome.<br/><br/>The clinically approved drug vismodegib, targets the Hedgehog signalling pathway via its receptor, Smoothened and has been tested in clinical trials for pancreatic cancer. This pathway is involved in the activation of CAFs via paracrine signalling from the tumour cells. Despite …
-
An oral physiologically-based pharmacokinetic model to predict drug absorption and disposition of vismodegib
… approach for prospective predictions using vismodegib (Erivedge®) as a model drug. Vismodegib is a poorly soluble drug, similar to many compounds currently in development, with unanticipated nonlinear PK behavior in humans. For a 150 mg oral dose, accumulation was roughly 5-fold lower than …
-
Vismodegib – Inhibitor des Hedgehog-Signaltransduktionsweges – in der ex-vivo-Chemoresponsetestung bei Kopf-Hals-Tumoren
… associates with poor prognosis. The Hh inhibitor vismodegib targets smoothened (SMO) and, based on molecular data, may prevent resistance to EGFR targeting. Methods: To elucidate potential roles of vismodegib in HNSCC therapy, its sole effects and those combined with cisplatin, docetaxel, and …
-
A comparative retrospective study of Mohs micrographic surgery and vismodegib chemotherapy for the treatment of advanced basal cell carcinoma
… micrographic surgery and the pharmaceutical drug vismodegib. Few studies have sought to compare the two methods using these criteria, and as vismodegib has only received FDA approval in the past ten years, it is worthwhile to explore the limitations and advantages of each therapy. In exploring …
-
Effect of Cilengitide and Vismodegib on Primary Cell Cultures and Cell Lines of Head and Neck Squamous Cell Carcinoma (HNSCC) after Targeting Integrin and Hedgehog Pathways
… plays a critical role during cancer development. Vismodegib (GDC-0449) is an orally administered agent that selectively suppresses SMO activity. Most previous studies used cell lines purchased from commercial companies. These cell lines may already have differentiated and lost some of their …
-
Effects of sonic hedgehog inhibition on behavior and metabolism of basal cell carcinoma cells and fibroblasts
… and metastatic BCCs. Systemic treatment with vismodegib, a potent SMO inhibitor, can effectively reduce BCC tumor burden in adult Gorlin syndrome patients. However, it is associated with chemotherapy-related adverse events, and treatment cessation results in cancer recurrence and formation of …
-
Targeting Canonical and Noncanonical Hedgehog Signaling Pathways in Cancer
… that survive treatment with the Hh inhibitor vismodegib. Combination of FDA approved Hh inhibitor vismodegib and MBZ resulted in additive Hh signaling inhibition. Because MBZ can be safely administered to adults and children at high doses over extended time periods, I propose that MBZ could be …
-
Characterization and Inhibition of Canine Osteosarcoma Tumor-Initiating Cells
… Two smoothened-inhibiting drugs, cyclopamine and vismodegib, were used to block the hedgehog pathway in canine osteosarcoma cell lines in both in vitro and in vivo studies. The second target, HER2, was upregulated in both differentiated osteosarcoma cells and TICs. Lapatinib was used to block HER2 …
-
Einflüsse der kommensalen Mikrobiota und der Altered Schaedler Flora auf epitheliale Entzündungsprozesse und die Morphologie der Dünndarmmukosa
… durch Applikation des Inhibitors Vismodegib gehemmt. Ein möglicher Einfluss auf die Permeabilität des Dünndarms wurde über die mRNA-Expression diverser Tight Junction-Proteine wie Occludin oder Claudin-4 sowie durch einen Permeabilitätsassay mit FITC-Dextran untersucht. …
-
Pharmacotherapeutics targeting the hedgehog pathway: emerging treatments for metastatic basal cell carcinoma
… of the two current treatments for mBCC, Vismodegib and Sonidegib, and one potential treatment currently under investigation, Itraconazole/ATO. A review of the clinical research will detail the mechanism of action for each drug with regard to the HHP and its components, the efficacy of the …
-
Functional and Molecular Characterization of Hedgehog Signalling Regulation
… confers clinical resistance to the antagonist vismodegib in cancer treatment.
-
Elucidating The Role Of Hedgehog Signaling In Tumor Cell Response To Dna Damage And Microenvironmental Stress
… (PET) imaging upon the administration of Vismodegib, a FDA-approved Hh inhibitor in vivo. Furthermore, we uncovered the mechanistic role of Hh in enabling hypoxia adaptation through robust activation of HIF signaling in a VHL-dependent manner. In addition to modulating temporal changes in …
-
Pharmacological and structural studies on the hedgehog pathway receptor smoothened
… (TMD). The ligands targeting the SMO CRD inhibit vismodegib-resistant mouse SMO-D477G, and are currently undergoing medicinal chemistry optimisation to ultimately enable potential therapeutic applications. Furthermore, these compounds can be used in future structural and functional studies to …
-
Ascertainment of keratinocyte carcinoma and atopic dermatitis using health administrative data in British Columbia, Canada
… prescriptions for imiquimod, 5-fluorouracil, or vismodegib. High sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) was achieved with values of 86.6% (confidence interval: 79.2-94.0%), 97.4% (CI: 96.2-98.6%), 78.9% (CI: 70.5-87.3%), 98.5% (CI: …
-
Interactions between Pax6, Barhl2 and Shh in the early patterning of the mammalian diencephalon
… drug treatment with the Shh antagonist vismodegib led to an upregulation of Barhl2 and the loss of the GABAergic pTh-R in the Pax6-null mutant thalamus, but not in the wild type thalamus, suggesting that Pax6 and Shh may be required to inhibit Barhl2 in order for GABAergic neurogenesis …
-
Structural and biochemical characterization of USP28 inhibition by small molecule inhibitors
… of USP28 in complex with the AZ compounds, Vismodegib and FT206 reveal that all three inhibitor classes bind into the same allosteric pocket distant from the catalytic center, located between the palm and the thumb subdomains (the S1-site). Intriguingly, this binding pocket is identical to …
-
Investigate the role bromodomain- and plant homeodomain-linked zinc finger-containing protein 1 (BRPF1) plays in medulloblastoma
… that target SHH signaling. Most notably, vismodegib has shown great promise in the treatment of MB and other SHH-driven cancers by targeting Smoothened (SMO), an upstream regulator of GLI activity. However, most patients who had initially responded to the drug quickly acquired point …
-
Evaluation klinischer Parameter sowie immunhistochemische Untersuchungen von Patient:innen mit odontogener Keratozyste
Hintergrund: Die odontogene Keratozyste (OKC) ist eine Zyste odontogenen Ursprungs im Kieferknochen und tritt sowohl syndromal als auch sporadisch auf. Die hohe Rezidivrate von OKCs nach operativer Entfernung stellt nach wie vor ein Problem dar. Beim Einsatz von Hedgehoginhibitoren bei …